瑞银
共 385 份研报 · 海外机构
华润建材科技（1313.HK）：近期复苏但盈利能力仍低
China Resources Building Materials (1313.HK): Near-term recovery, but low profitability persists
瑞银·2026-10-12·19 页·港股
大宗商品日报：特朗普暗示俄乌能源停火可能性
Daily Commodities Note: Trump indicates potential Russia-Ukraine energy ceasefire
瑞银·2026-10-12·16 页·有色金属
大中华区银行每日速报：9月制造业PMI录得50.1%，环比上行0.3个百分点；财政部盘活5500亿元闲置地方债额度
Greater China Banks Daily: September Manufacturing PMI recorded 50.1%, up 3bps MoM; MoF deploys RMB 550bn in unused local debt quota
瑞银·2026-10-12·15 页·金融
瑞银-Vylor（VYLR.US）：播撒未来增长种子，首次覆盖给予“买入”评级
Vylor Inc: Seeding the Growth of Tomorrow; Initiate Buy
瑞银·2026-10-12·49 页·美股
Ovintiv（OVV.US）：2026年三季度前瞻——克服中游业务逆风，展望持续改善
Ovintiv Inc 3Q26 Preview - Improving Outlook Despite Midstream Headwinds
瑞银·2026-10-12·15 页·美股
Oscar Health（OSCR.US）：预计三季度业绩稳健，调整盈利预测
Expecting a Solid 3Q; Adjusting Estimates
瑞银·2026-10-12·17 页·美股
英国股票：跌倒并未出局
UK Equities: Down, Not Out
瑞银·2026-10-12·28 页·市场策略
Crescent Energy（CRGY.US）：交易后回顾：资本效率提升对冲短期债务增加
Crescent Energy (CRGY): Post-Deal Review: Cap. Efficiency Gains vs. Higher N-T Debt
瑞银·2026-10-12·17 页·美股
Alignment Healthcare（ALHC.US）：需克服诸多逆风
Alignment Healthcare (ALHC.US): A Number of Headwinds to Work Through
瑞银·2026-10-12·17 页·美股
友邦保险（1299.HK）：2026年三季度业绩预览，黎明前的黑暗
友邦保险 (1299.HK): AIA Group: Q326 preview: darkness before dawn
瑞银·2026-10-11·12 页·港股
双汇发展（000895.SZ）：预计因食品安全事件的监管处罚将使2026年净利润减少6380万元
双汇发展 (000895.SZ): Shuanghui expects regulatory penalty involving food safety incident to reduce 2026 NP by Rmb63.8mn
瑞银·2026-10-11·11 页·A股
道路与火花：为何需要关注动力总成结构占比
Road & Spak: Why you should pay attention to powertrain mix
瑞银·2026-10-11·28 页·交运设备
瑞银-Tectonic Therapeutic（TECX.US）：临床试验成功也可能不及预期：首次覆盖给予“中性”评级
Tectonic Therapeutic Inc: A Positive Trial Could Still Disappoint - Initiate at Neutral
瑞银·2026-10-11·51 页·美股
Spyre Therapeutics（SYRE.US）：仍有更多机会，首次覆盖给予“买入”评级
Spyre Therapeutics: There's More to Play For - Initiate at Buy
瑞银·2026-10-11·71 页·美股
Shattuck Labs（STTK.US）：暂离焦点但未退出TL1A赛道，首次覆盖给予"买入"评级
Shattuck Labs Inc (STTK): Off the Radar, but Not Out of the (TL1A) Race - Initiate at Buy
瑞银·2026-10-11·52 页·美股
Protagonist Therapeutics（PTGX.US）：特许权使用费支撑可持续性，首次覆盖给予“买入”评级
Protagonist Therapeutics (PTGX.US): Royalties Funding Repeatability - Initiate at Buy
瑞银·2026-10-11·65 页·美股
Odyssey Therapeutics（ODTX.US）：IBD领域前景广阔的全新口服疗法，催化剂在2027年下半年——首次覆盖给予“买入”评级
Odyssey Therapeutics Inc (ODTX): Promising New Oral Approach in IBD; Catalyst in 2H27 - Initiate at Buy
瑞银·2026-10-11·48 页·美股
Ocular Therapeutix（OCUL.US）：差异化长效视网膜疗法临近上市，首次覆盖给予"买入"评级
Ocular Therapeutix Inc: Differentiated Long-Acting Retina Therapy Approaching Market - Initiate at Buy
瑞银·2026-10-11·53 页·美股
Monte Rosa Therapeutics（GLUE.US）：ZEUS并未推翻炎症相关假说，MRT-8102提供差异化切入角度——首次覆盖给予“买入”评级
Monte Rosa Therapeutics Inc (GLUE): ZEUS Didn't Break the Inflammation Thesis; MRT-8102 Offers a Different Angle - Assume at Buy
瑞银·2026-10-11·61 页·美股
Kodiak Sciences（KOD.US）：美国眼科学会专家小组对Tarco产品的耐用性以及"干化后再治疗"复治标准看法偏乐观
瑞银·2026-10-11·14 页·美股
显示 101 - 120 条，共 385 条